American CryoStem Corporation (CRYO) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CRYO steht fuer American CryoStem Corporation, ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Bewertet mit 46/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 2026American CryoStem Corporation (CRYO) Gesundheitswesen & Pipeline-Uebersicht
American CryoStem Corporation develops and licenses adipose tissue-derived technologies for regenerative medicine, offering products like CELLECT and ATGRAFT. Operating within the biotechnology sector, the company provides solutions for tissue collection, storage, and cell culture, targeting personalized medicine applications, while facing competition in a dynamic market.
Investmentthese
American CryoStem Corporation operates in the burgeoning regenerative medicine sector, offering potential for growth as personalized medicine gains traction. However, the company's negative P/E ratio of -0.00 and a significantly negative profit margin of -13985.4% raise concerns about its financial sustainability. A high beta of 11.42 indicates extreme volatility, making it a high-risk investment. Key value drivers include the expansion of its product line and strategic partnerships within the regenerative medicine space. Upcoming catalysts involve the potential FDA approvals for adipose tissue-derived therapies. However, the company's small size, with only 4 employees, and its listing on the OTC market present significant risks.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap of $0.00B indicates the company is a microcap stock with limited liquidity.
- P/E Ratio of -0.00 reflects the company's lack of profitability.
- Profit Margin of -13985.4% highlights significant financial challenges.
- Gross Margin of 34.1% suggests some efficiency in core operations despite overall losses.
- Beta of 11.42 indicates extreme volatility compared to the market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary adipose tissue-derived technologies.
- Comprehensive product line covering collection, storage, and cell culture.
- Contract manufacturing capabilities for specialized formulations.
- Established presence in the regenerative medicine market.
Schwaechen
- Negative profitability and high operating losses.
- Small size and limited resources.
- High beta indicating extreme volatility.
- Dependence on a niche market segment.
Katalysatoren
- Upcoming: Potential FDA approvals for adipose tissue-derived therapies.
- Ongoing: Expansion of strategic partnerships within the regenerative medicine space.
- Ongoing: Increasing adoption of CELLECT collection system by physicians.
- Ongoing: Growing demand for ATGRAFT adipose tissue storage services.
- Ongoing: Development of new ACSelerat cell culture media formulations.
Risiken
- Potential: Intense competition in the regenerative medicine market.
- Potential: Regulatory hurdles and approval delays.
- Potential: Technological advancements rendering current technologies obsolete.
- Ongoing: Negative profitability and high operating losses.
- Ongoing: Limited financial disclosure due to OTC Other status.
Wachstumschancen
- Expansion of CELLECT System Adoption: The CELLECT collection, transportation, and storage system offers a growth opportunity by targeting physicians seeking efficient tissue sample handling solutions. The market for such systems is growing as regenerative medicine practices expand. Increased adoption could be driven through targeted marketing and partnerships with medical clinics, potentially capturing a larger share of the tissue collection market within the next 2-3 years.
- Increased ATGRAFT Service Utilization: The ATGRAFT adipose tissue storage service can drive growth by catering to patients seeking long-term storage of their tissue for future regenerative therapies. As awareness of regenerative medicine benefits increases, demand for tissue storage services will likely grow. By offering competitive pricing and secure storage solutions, American CryoStem can attract more customers and expand its storage service revenue within the next 5 years.
- Development of Novel ACSelerat Media Formulations: The ACSelerat cell culture media products present a growth opportunity by catering to researchers and institutions involved in cell-based therapies. The market for cell culture media is expanding with advancements in cell biology and regenerative medicine. Developing specialized media formulations for different cell types can differentiate American CryoStem and capture a larger share of the cell culture media market within the next 3-4 years.
- Strategic Partnerships for Autokine-CM Manufacturing: The contract manufacturing services for Autokine-CM, an anti-aging topical formulation, offer a growth opportunity by leveraging existing manufacturing capabilities. Partnering with dermatology clinics and skincare companies can expand the reach of Autokine-CM and increase manufacturing revenue. Establishing long-term manufacturing agreements can provide a stable revenue stream within the next 2 years.
- Licensing of Adipose Tissue-Derived Technologies: Licensing its adipose tissue-derived technologies to other companies in the regenerative medicine space can generate revenue and expand market reach. The demand for innovative regenerative medicine technologies is high. By actively seeking licensing agreements, American CryoStem can monetize its intellectual property and establish a presence in new markets within the next 3-5 years.
Chancen
- Expansion of CELLECT system adoption.
- Increased ATGRAFT service utilization.
- Development of novel ACSelerat media formulations.
- Strategic partnerships for Autokine-CM manufacturing.
Risiken
- Intense competition in the regenerative medicine market.
- Regulatory hurdles and approval processes.
- Technological advancements rendering current technologies obsolete.
- Economic downturn impacting demand for regenerative medicine services.
Wettbewerbsvorteile
- Proprietary adipose tissue-derived technologies.
- Established presence in the regenerative medicine market since 1987.
- Comprehensive product line including collection systems, storage services, and cell culture media.
- Contract manufacturing capabilities for specialized formulations like Autokine-CM.
Ueber CRYO
American CryoStem Corporation, founded in 1987 and based in Eatontown, New Jersey, is a biotechnology company focused on regenerative and personalized medicine. The company develops, markets, and licenses technologies derived from adipose tissue. Its core offerings include the CELLECT collection, transportation, and storage system, designed to facilitate the collection and delivery of tissue samples by physicians. ATGRAFT adipose tissue storage service provides a comprehensive solution for fat collection, processing, and storage, enabling physicians to offer tissue products and cell storage options to their patients. ATCELL adipose-derived stem cells are also part of their product line. Additionally, American CryoStem offers ACSelerat cell culture media products, specifically formulated for growing human stromal cells. Beyond its core product lines, the company provides contract manufacturing services for Autokine-CM, an anti-aging topical formulation, and an autologous skin care product line. American CryoStem aims to be a key player in the regenerative medicine field by providing comprehensive solutions for tissue and cell-based therapies.
Was das Unternehmen tut
- Develop adipose tissue-derived technologies.
- Market regenerative and personalized medicine solutions.
- Offer CELLECT collection, transportation, and storage systems for tissue samples.
- Provide ATGRAFT adipose tissue storage services.
- Offer ATCELL adipose-derived stem cells.
- Supply ACSelerat cell culture media products.
- Provide contract manufacturing services for Autokine-CM.
- Offer an autologous skin care product line.
Geschaeftsmodell
- Selling CELLECT collection, transportation, and storage systems to physicians.
- Providing ATGRAFT adipose tissue storage services to patients.
- Selling ACSelerat cell culture media products to researchers and institutions.
- Generating revenue through contract manufacturing services for Autokine-CM.
- Licensing adipose tissue-derived technologies to other companies.
Branchenkontext
American CryoStem Corporation operates within the regenerative medicine and biotechnology industry, a sector characterized by rapid innovation and increasing demand for personalized therapies. The market is driven by advancements in stem cell research and a growing aging population seeking anti-aging solutions. The competitive landscape includes companies focused on cell therapies, tissue engineering, and regenerative medicine products. American CryoStem's focus on adipose tissue-derived technologies positions it within a niche segment of this broader market, requiring it to compete with both specialized firms and larger players in the biotechnology space.
Wichtige Kunden
- Physicians seeking tissue collection and storage solutions.
- Patients interested in regenerative medicine and tissue storage.
- Researchers and institutions involved in cell-based therapies.
- Dermatology clinics and skincare companies utilizing Autokine-CM.
- Other companies in the regenerative medicine space licensing technologies.
Finanzdaten
Chart & Info
American CryoStem Corporation (CRYO) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer CRYO verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CRYO.
Kursziele
Wall-Street-Kurszielanalyse fuer CRYO.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CRYO auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: John S. Arnone
CEO
John S. Arnone serves as the CEO of American CryoStem Corporation. Information regarding his detailed career history, education, and previous roles is not available in the provided data. However, as CEO, he is responsible for the overall strategic direction and management of the company, guiding its efforts in the regenerative and personalized medicine fields.
Erfolgsbilanz: As CEO, John S. Arnone is responsible for overseeing the development, marketing, and licensing of American CryoStem's adipose tissue-derived technologies. His leadership is focused on expanding the company's product line, securing strategic partnerships, and navigating the regulatory landscape. Specific achievements and milestones under his leadership are not detailed in the provided data.
CRYO OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that American CryoStem Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to file regular reports with the SEC, unlike companies listed on major exchanges like the NYSE or NASDAQ, which have stringent listing requirements and reporting obligations.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure due to OTC Other status.
- Low trading volume and liquidity.
- Higher potential for price manipulation.
- Increased risk of fraud or mismanagement.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and technology.
- Review any legal or regulatory issues involving the company.
- Monitor trading volume and price volatility.
- Consult with a financial advisor.
- Long operating history since 1987.
- Focus on regenerative medicine, a growing field.
- Proprietary adipose tissue-derived technologies.
- Presence of a CEO, John S. Arnone.
American CryoStem Corporation Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for CRYO?
American CryoStem Corporation (CRYO) currently holds an AI score of 46/100, indicating low score. Key strength: Proprietary adipose tissue-derived technologies.. Primary risk to monitor: Potential: Intense competition in the regenerative medicine market.. This is not financial advice.
How frequently does CRYO data refresh on this page?
CRYO prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CRYO's recent stock price performance?
Recent price movement in American CryoStem Corporation (CRYO) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary adipose tissue-derived technologies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CRYO overvalued or undervalued right now?
Determining whether American CryoStem Corporation (CRYO) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CRYO?
Before investing in American CryoStem Corporation (CRYO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CRYO to a portfolio?
Potential reasons to consider American CryoStem Corporation (CRYO) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary adipose tissue-derived technologies.. Additionally: Comprehensive product line covering collection, storage, and cell culture.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CRYO?
Yes, most major brokerages offer fractional shares of American CryoStem Corporation (CRYO) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CRYO's earnings and financial reports?
American CryoStem Corporation (CRYO) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CRYO earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Financial data is limited due to the company's OTC Other status and lack of comprehensive reporting.
- AI analysis is pending, so some insights are based on available profile information.